SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : NKTR Drug delivery Company
NKTR 55.97+1.5%Nov 7 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Miljenko Zuanic who wrote (418)10/1/2018 6:59:40 PM
From: Miljenko Zuanic1 Recommendation

Recommended By
ghmm

  Read Replies (1) of 507
 
Main explanation of the "short" report is absence of the effect-Lymphocyte level increase after NK-214 v IL-2 , 30-50% for NK-214 versus +200% peak for IL-2. Hoover, from ASCO presentation, SL51/52 ( nektar.com ) paint different picture for NK-214/Nivo combination. Significant difference in blood proTeffect v proTreg cell count, favoring CD8+ proTcells.

There is visible improvement in NK214 performance (mechanistically) when it is combined with anti-PD1 therapy, most notably in cancer biopsy markers.

In all, "short" have good point relative to current NK-214 results. Only way to oppose short hypothesis is real world bio-marker data and tumor response results.

At SITC NKTR will present full melanoma cohort, so it may be turning point. Have no idea what to expect,.... too many Qs from disappointing ASCO presentations.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News